SLC5A2 and metabolic dysfunction-associated steatotic liver disease: For the treatment of NAFLD, SGLT2 inhibitors are a relatively new drug class for the treatment of T2DM that may be beneficial therapeutic option after further studies evaluating the safety, efficacy, and tolerability in this sub-population.